Antiplatelet drugs in cardiological practice: established strategies and new developments

Area of Science:

• Cardiovascular Research
• Hematology
• Pharmacology

Background:

• Platelet activation and aggregation are central to vascular diseases like atherothrombosis.
• Thrombotic complications of atherosclerosis contribute significantly to mortality from cerebral, coronary, and peripheral arterial ischemia.
• Pharmaceutical research prioritizes novel therapies and improved strategies for platelet-dependent thrombosis.

Purpose of the Study:

• To summarize the pathophysiology of platelet activation in vascular diseases.
• To present current concepts in antiplatelet drug therapy.
• To highlight the role of platelets beyond atherothrombosis.

Main Methods:

• Review of current literature on platelet pathophysiology and antiplatelet therapies.
• Analysis of established and emerging antiplatelet drug targets and mechanisms.
• Exploration of platelet involvement in various vascular conditions.

Main Results:

• Platelet hyperactivation is a common pathway in vascular diseases, leading to atherothrombosis.
• Established antiplatelet agents are undergoing re-evaluation for efficacy, dosing, and indications.
• Novel molecular targets for inhibiting platelet activity are emerging, offering new therapeutic avenues.

Conclusions:

• Understanding platelet roles in atherosclerosis is crucial for developing effective treatments.
• New therapeutic options are arising from research into molecular targets.
• Platelets play a significant role in vascular diseases beyond their involvement in atherothrombosis.